TABLE 1.

Patient characteristics based on apolipoprotein A quartiles.

Apolipoprotein A1 quartile	Q1	Q2	Q3	Q4	P-value	P-value*
N	535	568	542	563
Lumber BMD, g/cm2	0.73 ± 0.15	0.72 ± 0.15	0.75 ± 0.17	0.77 ± 0.15	0.004	0.002
β-CTX, ng/mL	0.58 ± 0.35	0.55 ± 0.28	0.53 ± 0.25	0.51 ± 0.24	0.184	0.564
Age, year	70.17 ± 11.57	68.96 ± 11.22	68.76 ± 10.55	68.45 ± 11.25	0.061	0.053
BMI categorical, N (%)	22.82 ± 3.44	23.04 ± 3.43	23.17 ± 3.45	22.87 ± 3.33	0.304	0.432
Triglycerides, mmol/L	1.16 ± 0.79	1.22 ± 0.90	1.29 ± 0.87	1.26 ± 1.19	0.107	0.136
ALT, IU/L	21.59 ± 15.10	23.25 ± 30.04	23.33 ± 19.96	22.05 ± 13.30	0.411	0.066
UA, μmol/L	295.80 ± 95.95	284.30 ± 90.79	275.92 ± 88.16	271.41 ± 87.46	<0.001	<0.001
Monocyte, × 109/L	0.54 ± 0.26	0.52 ± 0.49	0.47 ± 0.24	0.46 ± 0.22	<0.001	<0.001
Hemoglobin, g/L	121.25 ± 20.68	126.69 ± 18.22	127.09 ± 16.94	128.63 ± 14.89	<0.001	<0.001
Platelet, × 109/L	172.35 ± 67.79	178.18 ± 61.20	175.37 ± 61.16	180.52 ± 55.88	0.146	0.010
HDL, mmol/L	1.07 ± 0.19	1.26 ± 0.19	1.40 ± 0.21	1.64 ± 0.30	<0.001	<0.001
LDL, mmol/L	2.26 ± 0.76	2.54 ± 0.75	2.66 ± 0.72	2.72 ± 0.75	<0.001	<0.001
Neutrophil, × 109/L	6.42 ± 3.24	6.29 ± 2.99	6.11 ± 2.83	6.48 ± 3.05	0.194	0.225
FAR	0.08 ± 0.03	0.07 ± 0.02	0.07 ± 0.02	0.07 ± 0.02	<0.001	<0.001
PTH, pg/mL	16.29 ± 12.72	14.81 ± 11.42	14.30 ± 8.84	13.25 ± 7.44	<0.001	0.002
Diabetes					0.153	–
No	511 (95.51%)	555 (97.71%)	521 (96.13%)	537 (95.38%)
Yes	24 (4.49%)	13 (2.29%)	21 (3.87%)	26 (4.62%)
Hypertension					0.943	–
No	465 (86.92%)	495 (87.15%)	469 (86.53%)	484 (85.97%)
Yes	70 (13.08%)	73 (12.85%)	73 (13.47%)	79 (14.03%)

*Kruskal-Wallis rank test for continuous variables, Fisher exact for categorical variables with expects < 10. APOA1, apolipoprotein A1; Lumber BMD, lumbar spine bone density; β-CTX, C-terminal telopeptide of type I collagen; BMI, body mass index; ALT, alanine aminotransferase; UA, uric acid; PTH, parathyroid hormone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FAR, fibrinogen/albumin ratio.